Skip to content

Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department

Evaluation of Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Undergoing Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07765030
Enrollment
150
Registered
2026-08-14
Start date
2026-08-10
Completion date
2026-11-01
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Kidney Failure, Kidney Failure, Acute

Keywords

Emergency Renal Replacement Therapy, Hemodialysis, Continuous Venovenous Hemodiafiltration, Acute Kidney Injury, In-Hospital Mortality

Brief summary

This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026. Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes. The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.

Detailed description

Emergency renal replacement therapy may be required in critically ill patients with life-threatening conditions such as severe hyperkalemia, refractory metabolic acidosis, fluid overload or pulmonary edema, uremic complications, acute kidney injury, acute deterioration in patients with chronic kidney disease, sepsis-associated renal dysfunction, cardiorenal syndrome, or selected intoxications. In routine clinical practice, these patients are generally managed in intensive care settings. However, when intensive care capacity is limited or transfer to the hospital dialysis unit is not clinically feasible, renal replacement therapy may need to be initiated and continued in an emergency department critical care area. This single-center, retrospective, observational, descriptive-analytical study will review the medical records of critically ill adult patients who received hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026. Data will be obtained from the hospital information management system, electronic medical records, laboratory records, clinical follow-up notes, renal replacement therapy records, and discharge summaries. The study will characterize the clinical profile of patients requiring emergency renal replacement therapy and examine treatment indications, treatment modality, treatment course, pre- and post-treatment laboratory findings, treatment-related complications, and in-hospital clinical outcomes. Renal replacement therapy indications will be evaluated under predefined clinical categories, and patients with more than one indication may be classified in more than one category. Laboratory changes, particularly in potassium, pH, bicarbonate, urea, creatinine, and lactate, will be assessed using available routine clinical measurements before and after treatment. The study is intended to provide descriptive and exploratory evidence regarding the use of HD and CVVHDF in critically ill patients managed in the emergency department and to contribute to the evaluation of emergency critical care processes in settings where intensive care capacity may be limited. No study-specific intervention will be performed, and all analyses will be based exclusively on routinely collected retrospective clinical data.

Interventions

Hemodialysis performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.

PROCEDUREContinuous Venovenous Hemodiafiltration (CVVHDF)

Continuous venovenous hemodiafiltration performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.

Sponsors

Antalya Health Sciences University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older. * Followed in the critical care area of the Emergency Department of Antalya * Training and Research Hospital between January 1, 2023, and August 1, 2026. * Presence of an indication for emergency renal replacement therapy. * Underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the emergency department. * Required critical care-level monitoring or management. * Availability of sufficient demographic, clinical, laboratory, and in-hospital outcome data in the hospital information system, electronic medical records, laboratory records, or clinical follow-up notes.

Exclusion criteria

* Age younger than 18 years. * Renal replacement therapy initiated outside the emergency department. * Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department. * Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed. * Missing essential clinical, laboratory, or in-hospital outcome data. In patients with repeated emergency department admissions, only the first emergency renal replacement therapy episode will be included to reduce statistical dependency.

Design outcomes

Primary

MeasureTime frameDescription
In-Hospital MortalityUp to 30 days from emergency department admissionNumber and proportion of patients who die during the index hospitalization following emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF).

Secondary

MeasureTime frameDescription
Emergency Department MortalityUp to 1 day from emergency department admissionNumber and proportion of patients who die during their emergency department stay.
Intensive Care Unit AdmissionUp to 1 day from emergency department admissionNumber and proportion of patients requiring admission to an intensive care unit following emergency renal replacement therapy.
Renal Replacement Therapy-Related ComplicationsUp to 8 hours from emergency department admissionNumber and proportion of patients experiencing complications during renal replacement therapy, including hypotension, arrhythmia, cardiac arrest, bleeding, catheter-related problems, or device/technical problems.

Countries

Turkey (Türkiye)

Contacts

CONTACTmurat Duyan, ASSOCIATE PROFESSOR
drmuratduyan@gmail.com+90 540 412 0735

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026